

**Radline Medical Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 31 October 2025**

**Radline Medical Limited**  
**CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Statement of Financial Position	4
Reconciliation of Shareholders' Funds	5
Notes to the Financial Statements	6 - 8

# Radline Medical Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 October 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently.
- make judgements and accounting estimates that are reasonable and prudent.
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Statement of Financial Position, the Reconciliation of Shareholders' Funds and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them.

The directors confirm that they have made available to Kilcoyne & Co Accountants, (Chartered Accountants Ireland), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 October 2025."

### Signed on behalf of the board

---

**Pascal Paul Servell**  
Director

**25 March 2026**

---

**Christelle Servell**  
Director

**25 March 2026**

# Radline Medical Limited

## STATEMENT OF FINANCIAL POSITION

as at 31 October 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Tangible assets	5	1,972	1,236
Investments	6	141,676	133,247
<b>Fixed Assets</b>		<b>143,648</b>	<b>134,483</b>
<b>Current Assets</b>			
Debtors	7	5,753	850
Cash at bank and in hand		3,361	25,967
		<b>9,114</b>	<b>26,817</b>
<b>Creditors: amounts falling due within one year</b>	8	<b>(4,038)</b>	<b>(2,260)</b>
<b>Net Current Assets</b>		<b>5,076</b>	<b>24,557</b>
<b>Total Assets less Current Liabilities</b>		<b>148,724</b>	<b>159,040</b>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		100	100
Other reserves	9	-	42,969
Retained earnings		148,624	115,971
<b>Shareholders' Funds</b>		<b>148,724</b>	<b>159,040</b>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Radline Medical Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 25 March 2026 and signed on its behalf by:

\_\_\_\_\_  
Pascal Paul Servell  
Director

\_\_\_\_\_  
Christelle Servell  
Director

**Radline Medical Limited**  
**RECONCILIATION OF SHAREHOLDERS' FUNDS**

as at 31 October 2025

	Called up share capital €	Retained earnings €	Investment property reserve €	Total €
<b>At 1 November 2023</b>	100	129,623	-	129,723
Loss for the financial year	-	(13,652)	-	(13,652)
Other gains and losses	-	-	42,969	42,969
Total comprehensive income	-	(13,652)	42,969	29,317
<b>At 31 October 2024</b>	100	115,971	-	116,071
Profit for the financial year	-	32,653	-	32,653
<b>At 31 October 2025</b>	<b>100</b>	<b>148,624</b>	-	<b>148,724</b>

# Radline Medical Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

### 1. General Information

Radline Medical Limited is a company limited by shares incorporated in Ireland. The registered office of the company is Coliemore House, Coliemore Road, Dalkey, Co. Dublin which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 31 October 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Turnover comprises the invoice value of services supplied by the company, exclusive of trade discounts and value added tax.

Turnover from the provision of services is recognised in the accounting period in which the services are rendered and the outcome of the contract can be estimated reliably. The company uses the percentage of completion method based on the actual service performed as a percentage of the total services to be provided.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	12.5% Straight line
----------------------------------	---	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Investments

Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related withholding tax is recognised in the Profit and Loss Account in the financial year in which it is receivable.

#### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

## Radline Medical Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

### Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

<b>3. Operating loss</b>	<b>2025</b>	2024
	€	€
<b>Operating loss is stated after charging:</b>		
Depreciation of tangible assets	<b>388</b>	247
	<u><u>388</u></u>	<u><u>247</u></u>
<b>4. Other Gains and Losses</b>	<b>2025</b>	2024
	€	€
Fair value gains and losses are as follows:		
	<b>51,817</b>	-
	<u><u>51,817</u></u>	<u><u>-</u></u>
<b>5. Tangible assets</b>		
	<b>Fixtures, fittings and equipment</b>	<b>Total</b>
	€	€
<b>Cost</b>		
At 1 November 2024	1,977	1,977
Additions	1,124	1,124
	<u>3,101</u>	<u>3,101</u>
At 31 October 2025	3,101	3,101
<b>Depreciation</b>		
At 1 November 2024	741	741
Charge for the financial year	388	388
	<u>1,129</u>	<u>1,129</u>
At 31 October 2025	1,129	1,129
<b>Net book value</b>		
At 31 October 2025	<b>1,972</b>	<b>1,972</b>
	<u><u>1,972</u></u>	<u><u>1,972</u></u>
At 31 October 2024	1,236	1,236
	<u><u>1,236</u></u>	<u><u>1,236</u></u>
<b>6. Investments</b>		
	<b>Other unlisted investments</b>	<b>Total</b>
	€	€
<b>Investments Cost or Valuation</b>		
At 1 November 2024	133,247	133,247
Revaluations	8,429	8,429
	<u>141,676</u>	<u>141,676</u>
At 31 October 2025	141,676	141,676
<b>Net book value</b>		
At 31 October 2025	<b>141,676</b>	<b>141,676</b>
	<u><u>141,676</u></u>	<u><u>141,676</u></u>
At 31 October 2024	133,247	133,247
	<u><u>133,247</u></u>	<u><u>133,247</u></u>

## Radline Medical Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 October 2025

<b>7. Debtors</b>	<b>2025</b>	<b>2024</b>
	€	€
Trade debtors	123	750
Other debtors	100	100
Directors' current accounts	5,530	-
	<u>5,753</u>	<u>850</u>
<b>8. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due within one year</b>	€	€
Taxation	1,383	-
Accruals	2,655	2,260
	<u>4,038</u>	<u>2,260</u>
<b>9. Profit and loss account</b>	<b>2025</b>	<b>2024</b>
	€	€
At 1 November 2024	115,971	129,623
Profit/(loss) for the financial year	32,653	(13,652)
At 31 October 2025	<u>148,624</u>	<u>115,971</u>
<b>10. Capital commitments</b>		
The company had no material capital commitments at the financial year-ended 31 October 2025.		
<b>11. Related party transactions</b>		
As the company has no employees the disclosure with regard to directors remuneration is not applicable.		
<b>12. Events After the End of the Reporting Period</b>		
There have been no significant events affecting the company since the financial year-end.		
<b>13. Changes in Equity</b>		
<b>Other Comprehensive Income</b>	<b>2025</b>	<b>2024</b>
	€	€
unlisted Investment revaluation in year	-	42,969
	<u>-</u>	<u>42,969</u>
<b>14. Approval of financial statements</b>		
The financial statements were approved and authorised for issue by the board of directors on 25 March 2026.		